AS1411-Lipm[siRNA] treatment led to a notable rise in proportion of Annexin V-positive cells (32.34 ± 7.82%), nearly doubling that observed with Lipm[siRNA] (15.33 ± 3.21%) and exceeding all other groups, indicating enhanced apoptosis through selective siRNA delivery to nucleolin-positive cancer cells. The gene discussed is NUCLEOLIN; the disease is cancer.